Concept Life Sciences has partnered with OpenBench to expand access to success based drug discovery services for early stage biotechnology companies. The collaboration combines Concept Life Sciences’ integrated CRO expertise with OpenBench’s AI enabled virtual screening platform to help accelerate the identification of novel drug candidates.

The partnership is designed to reduce early discovery risk and lower upfront costs for biotech innovators by offering a model where clients pay for successful outcomes rather than traditional fee for service structures. OpenBench’s platform is capable of screening vast chemical libraries to identify promising compounds, while Concept Life Sciences will provide integrated biology, chemistry and translational science support to move programs forward.

Both companies believe the collaboration will help smaller biotech firms gain access to advanced discovery capabilities that are often difficult to resource internally. The partnership also reflects growing industry demand for more flexible and efficient approaches to preclinical drug discovery.